Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temuterkib alone or in combination in advanced cancer
NCT02857270Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2016
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of temuterkib in cancer, melanoma, colorectal cancer (CRC) and 1 more (8 arms), sponsored by Eli Lilly and Company. Primary endpoint: Dose Limiting Toxicities. Started Sep 2016; status: completed.
02
Drugs
temuterkib
03
Conditions
cancermelanomacolorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02857270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02857270.